In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Third Wave Technologies IPO Will Fund Diagnostic Genotyping Tests

This article was originally published in The Gray Sheet

Executive Summary

Third Wave Technologies intends to develop clinical diagnostic tests for several inherited and infectious diseases, the firm said in its July 31 prospectus detailing a $100 mil. initial public offering.

You may also be interested in...



Breast, Prostate Imaging Regimens Would Be Aided By GEMS/Genometrix

GE Medical Systems will combine its molecular diagnostic imaging platform with Genometrix' microarray gene and protein analysis technology to develop biomarkers for breast and prostate cancer.

Breast, Prostate Imaging Regimens Would Be Aided By GEMS/Genometrix

GE Medical Systems will combine its molecular diagnostic imaging platform with Genometrix' microarray gene and protein analysis technology to develop biomarkers for breast and prostate cancer.

PE Biosystems/Third Wave Technologies

Termination of a January acquisition pact under which PE Biosystems would have acquired the Madison, Wisconsin-based developer of nucleic acid technologies for stock valued in the $300 mil. range will not prevent the firms from continuing to pursue joint collaborations, including several active projects, PE says (1"The Gray Sheet" Jan. 31, p. 19). "Recent discussions...led both companies to conclude that their collective interests would be best served if the companies remain independent but continue to collaborate," PE says in a May 25 release

Related Content

UsernamePublicRestriction

Register

MT013711

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel